Pharmaceutical News

RSS

UQDI reveals that Anisina drug can kill melanoma cells

US-Australian drug discovery company, Novogen, today announced that studies conducted at The University of Queensland Diamantina Institute revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status.

9 Apr 2015

Study: Viagra, other related drugs not a universal 'cure-all' for impotence

Viagra and other related drugs are not a universal 'cure-all' for impotence, according to a new study from The University of Manchester and NatCen Social Research.

9 Apr 2015

Vanderbilt researchers join multi-center effort to accelerate development of potential Ebola therapy

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.

9 Apr 2015

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the selection of RG-125 (AZD4076), a GalNAc-conjugated anti-miR targeting microRNA-103/107 (“miR-103/107”) for the treatment of Non Alcoholic Steatohepatitis (“NASH) in patients with type 2 diabetes/pre-diabetes, as a clinical candidate by AstraZeneca under the companies’ strategic alliance to discover, develop and commercialize microRNA therapeutics.

9 Apr 2015

UTMB scientists develop quick-acting vaccine that is effective against Ebola strain

An interdisciplinary team from The University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc. has developed a quick-acting vaccine that is both safe and effective with a single dose against the Ebola strain that killed thousands of people in West Africa last year.

8 Apr 2015

Uninsured cancer patients may face higher charges for chemotherapy drugs

Uninsured cancer patients are asked to pay anywhere from two to 43 times what Medicare would pay for chemotherapy drugs, according to a new study from the University of North Carolina at Chapel Hill.

8 Apr 2015

Experimental oligonucleotide-based drug stimulates human immune system to fight infections

An experimental single-stranded oligonucleotide-based drug, MGN1703, comprised only of natural DNA components, stimulates the human immune system to fight infections and attack cancer cells without causing the harmful side effects associated with similar compounds that also contain non-natural DNA components.

8 Apr 2015

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's.

8 Apr 2015

Northwestern University researchers find safer way to improve surgery outcomes

A Northwestern University research team potentially has found a safer way to keep blood vessels healthy during and after surgery.

7 Apr 2015

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Mylan N.V. today announced the U.S. launch of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable), which is the generic version of Warner Chilcott's Generess Fe Tablets.

7 Apr 2015

Medinatura now offers Traumeel and Zeel injections for knee OA

MediNatura Incorporated, a Delaware Corporation headquartered in greater Philadelphia, announced today that the company has become the exclusive importer for the following injection solutions: Traumeel, Zeel, LymphomyosotX, Spascupreel, Neuralgo-Rheum and Engystol.

7 Apr 2015

Antipsychotic drugs may elevate child's risk for weight gain, type II diabetes

Today in JAMA Pediatrics, researchers from The Children's Hospital of Philadelphia's (CHOP) PolicyLab published the largest study to date documenting the significant risks to children's health associated with prescription antipsychotics, a powerful a class of medications used to treat mental and behavioral health disorders.

7 Apr 2015

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen today announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC).

6 Apr 2015

Journal of Drugs in Dermatology publishes findings on new injectable drug ATX-101

The Journal of Drugs in Dermatology is pleased to publish findings on a new injectable drug currently under development by Kythera Biopharmaceuticals, Inc. (Westlake Village, CA) that may provide a non-surgical alternative for people with double chins.

6 Apr 2015

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Sanford-Burnham Medical Research Institute today announced that it has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease.

6 Apr 2015

Nanomedicine strategy can help reduce heart attacks, strokes

A research team showed that a nanotherapeutic medicine can halt the growth of artery plaque cells resulting in the fast reduction of the inflammation that may cause a heart attack, according to a study led by researchers from Icahn School of Medicine at Mount Sinai and published April 3 in Science Advances.

6 Apr 2015

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

6 Apr 2015

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg.

6 Apr 2015

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.

6 Apr 2015

Leukemia drug could prevent and control growth of colorectal tumours

Scientists from Nanyang Technological University (NTU Singapore) and Sweden's Karolinska Institutet, one of Europe's largest and most prestigious medical universities, have discovered that an existing chemotherapy drug used to treat leukaemia could prevent and control the growth of colorectal tumours.

3 Apr 2015

Pharmaceutical News

UQDI reveals that Anisina drug can kill melanoma cells

Study: Viagra, other related drugs not a universal 'cure-all' for impotence

Vanderbilt researchers join multi-center effort to accelerate development of potential Ebola therapy

AstraZeneca selects Regulus' RG-125 as clinical candidate for treatment of NASH

UTMB scientists develop quick-acting vaccine that is effective against Ebola strain

Uninsured cancer patients may face higher charges for chemotherapy drugs

Experimental oligonucleotide-based drug stimulates human immune system to fight infections

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

Northwestern University researchers find safer way to improve surgery outcomes

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Medinatura now offers Traumeel and Zeel injections for knee OA

Antipsychotic drugs may elevate child's risk for weight gain, type II diabetes

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Journal of Drugs in Dermatology publishes findings on new injectable drug ATX-101

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Nanomedicine strategy can help reduce heart attacks, strokes

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Leukemia drug could prevent and control growth of colorectal tumours

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News